General Information
Capmatinib is an orally bioavailable, adenosine triphosphate (ATP)– selective inhibitor of the MET tyrosine kinase domain that inhibits downstream signaling and subsequent tumor growth and progression.
About the API
Trade name(s)
Tabrecta
Technology
Synthetic
Molecular Formula
C23H17FN6O
Therapeutic category
Oncology
Available formulations
Oral Solid